admin

In Latest News

Russia, China practice destroying ‘enemy’ submarine in naval drill after Trump moves US nuclear assets

August 6, 2025 No Comments

The Russian and Chinese militaries practiced destroying an ‘enemy’ submarine during joint naval drills Wednesday, just days after President Donald Trump moved a pair of nuclear submarines toward Russia, a report said.

The drills involved Il-38 planes from Russia’s Pacific Fleet and Chinese Y-8 anti-submarine aircraft, according to Reuters, and came after Trump announced last Friday that he ‘ordered two Nuclear Submarines to be positioned in the appropriate regions’ following ‘highly provocative statements’ made by former Russian President Dmitry Medvedev.

‘As a result of effective joint actions, the ‘enemy’ submarine was promptly detected and mock-destroyed,’ Russia’s defense ministry said Wednesday following the naval exercises in the Sea of Japan, Reuters reported. ‘After practicing anti-submarine tasks, the crews of the Russian and Chinese ships thanked each other for their fruitful work.’

The White House and State Department did not immediately respond Wednesday to a request for comment from Fox News Digital.

White House envoy Steve Witkoff is preparing for a trip to Russia on Wednesday, two days ahead of Trump’s Aug. 8 deadline for Moscow to enter into a ceasefire with Ukraine or face stiff sanctions.

On Sunday, Trump told reporters that nuclear submarines he ordered to counter Russia are now ‘in the region.’

Medvedev said earlier last week that Trump’s new deadline for Russia to end the conflict with Ukraine is an additional ‘step towards war.’

‘Based on the highly provocative statements of the Former President of Russia, Dmitry Medvedev, who is now the Deputy Chairman of the Security Council of the Russian Federation, I have ordered two Nuclear Submarines to be positioned in the appropriate regions, just in case these foolish and inflammatory statements are more than just that,’ Trump then said in a post on Truth Social on Friday.

‘Words are very important, and can often lead to unintended consequences, I hope this will not be one of those instances,’ he added.

Fox News’ Diana Stancey, Danielle Wallace and Caitlin McFall contributed to this report.

This post appeared first on FOX NEWS

In Latest News

Vance, Bondi, Patel to huddle at VP residence for Epstein strategy meeting

August 6, 2025 No Comments

Vice President JD Vance is hosting senior Trump administration officials at his residence in Washington, D.C. on Wednesday evening for a strategy dinner to discuss how the administration should handle the ongoing Jeffrey Epstein fallout and move forward, Fox News has learned.

Vance has invited U.S. Attorney General Pam Bondi, FBI Director Kash Patel, and Deputy Attorney General Todd Blanche to dinner at the sprawling, 12-acre vice-presidential residence in Northwest Washington. White House chief of staff Susie Wiles is also expected to be in attendance, according to sources familiar.

News of the dinner was first reported by CNN. It comes after weeks of unsuccessful attempts by senior Trump officials to quell mounting public pressure to release more information related to the Epstein investigation — underscoring the sticking power of the Epstein scandal despite a fast-moving news cycle. Trump supporters have been among the leading voices demanding the release of additional information.

The Justice Department and the White House have also struggled to coordinate their messaging on the ongoing fallout from the Epstein scandal, following the release of an unsigned July 7 memo that said they did not plan to release additional information about the investigation.

Most recently, the White House and DOJ have been at odds over whether to release an audio file and transcript from Deputy Attorney General Todd Blanche’s interview with Epstein associate Ghislaine Maxwell late last month, senior administration officials confirmed.

It is unclear how long the audio footage and transcripts from the interviews between Blanche’s interview with Maxwell are, but they do exist, Fox News Digital reported yesterday, and discussions remain underway today involving whether — and when — to release the transcript.

Fox News Digital reported yesterday that DOJ officials have both the audio and transcript from Blanche’s interview with Maxwell, which took place over two days at the U.S. Attorney’s office near the Federal Correctional Institution in Tallahassee, Florida, where Maxwell had been serving out a 20-year prison sentence for sex trafficking.

Maxwell was transferred last week without explanation to a new, minimum-security women’s federal prison camp in Texas.

Anything released by the Trump administration would almost certainly involve heavily redacting any identifying information of individuals named in the transcript in order to protect victims — something Bondi has stressed in public on multiple occasions.

News of Vance’s dinner prompted fresh concerns from family members of one Epstein victim, Virginia Roberts Giuffre, who committed suicide earlier this year.

‘We understand that Vice President JD Vance will hold a strategy session this evening at his residence with administration officials,’ Giuffre’s sibling said in a statement Wednesday shared with Fox News Digital. ‘Missing from this group is, of course, any survivor of the vicious crimes of convicted perjurer and sex trafficker Ghislaine Maxwell and Jeffrey Epstein. Their voices must be heard, above all,’ they said.

‘We reiterate that Ghislaine Maxwell should have remained in a maximum security prison and does not deserve the luxuries currently afforded her.’

Pressure to release information has been unrelenting in the weeks since July 7, when the Justice Department said in an unsigned memo that it did not plan to release more information about the investigation. The Justice Department and FBI also said that investigators had not found a so-called ‘client list’ from Epstein, as had been suggested widely online, and by some Trump officials earlier this year.

Asked on Fox News in February about news that the DOJ would release ‘the list of Jeffrey Epstein’s clients,’ and when that would happen, Bondi replied, ‘It’s sitting on my desk right now to review.’

White House press secretary Karoline Leavitt later said Bondi had been referring more broadly to all the files related to Epstein, and not a single list.

This post appeared first on FOX NEWS

In Latest News

Trump blasts Schumer, Democrats as ‘country-hating thugs’ amid blockade on Senate nominees

August 6, 2025 No Comments

President Donald Trump lashed out at Senate Minority Leader Chuck Schumer on Wednesday, accusing the lawmaker of ‘extortion’ for holding up Trump’s nominees in the Senate.

Trump made the statement from his Truth Social account, arguing that never in U.S. history have so many of a president’s nominees been bottlenecked in the Senate. Senate Republicans had been negotiating with Schumer to speed up the nomination process this week, but the talks broke down.

‘Politically embattled Senator, Cryin’ Chuck Schumer, wants the Republicans to pay, as extortion, two billion dollars in order for the radical left Democrats to approve the hundreds of Trump appointments who have been waiting for months, and are raring to go,’ Trump wrote.

‘This has never happened before. There has never, in U.S. history, been such a delay. They are extortionists! Republicans must create legislation in order to get out of the grasp of these country-hating thugs. Move quickly!’ he added.

Lawmakers left Washington on Monday without a deal, leaving Republicans deeply frustrated with Schumer and Senate Democrats for their unprecedented filibustering of every one of Trump’s nominees. Only Secretary of State Marco Rubio received a smooth confirmation.

Schumer and the Democrats had demanded that Trump free up billions in funding for the National Institutes of Health (NIH) and foreign aid, accounting for Trump’s claims of a $2 billion ‘extortion.’

Republicans are now discussing a rule change that would block Democrats from filibustering the nominees, allowing them to clear the Senate with just a simple majority.

‘I think that way is going to happen anyways, because of what Schumer has done. He’s forced this, and it’s ridiculous that he’s doing this,’ Sen. Markwayne Mullin, R-Okla., said Tuesday. ‘And so, whatever, we’re at this point, and we’ll do, you know what they say, every action requires an equal [reaction], and that’s what we’re at right now.’

Currently, over 1,200 positions go through Senate confirmation. Senate Republicans have been able to confirm over 130 of Trump’s picks so far, but there are over 140 nominees still pending on the Senate’s calendar.

‘I think they’re desperately in need of change,’ Senate Majority Leader John Thune, R-S.D., told reporters on Tuesday. ‘I think that the last six months have demonstrated that this process, nominations, is broken. And so I expect there will be some good robust conversations about that.’

Fox News’ Alex Miller contributed to this report

This post appeared first on FOX NEWS

In Investing

First Quantum Secures US$1 Billion in Gold Stream Deal with Royal Gold

August 6, 2025 No Comments

First Quantum Minerals (TSX:FM,OTC Pink:FQVLF) has locked in a US$1.0 billion cash infusion through a gold streaming agreement with RGLD Gold AG, a wholly owned subsidiary of Royal Gold (NASDAQ:RGLD).

The Vancouver-based firm announced on Tuesday (August 5) that the streaming agreement is tied to its Zambian operations, covering future gold deliveries linked to copper output at its Kansanshi mine.

“Following a thorough evaluation of several deleveraging options, I am pleased to announce this milestone transaction which preserves exposure to all of the copper production at Kansanshi while still maintaining exposure to the majority of the Company’s gold production,” said First Quantum CEO Tristan Pascall in a press release.

“It is pleasing to form a new partnership with Royal Gold which is a strong endorsement of the operations at Kansanshi and its multi-generational ore body as well as Zambia as a leading African mining jurisdiction,” Pascall added.

The agreement provides First Quantum with long-term, unsecured capital that does not increase its debt load. Proceeds will be used for capital expenditures and repayment of existing bank loans. Furthermore, the company said that the transaction is expected to materially lower its net debt-to-EBITDA ratio.

While the arrangement commits First Quantum to deliver gold based on a formula tied to copper production, the company retains most of its gold upside.

Based on its 2026 and 2027 production forecasts, approximately 84 percent of its total gold output will still be exposed to spot market pricing. The company also retains full exposure to newly discovered near-surface gold zones at Kansanshi.

Under the terms of the agreement, First Quantum will deliver gold to Royal Gold on a stepdown basis: 75 ounces of gold for every million pounds of recovered copper produced until 425,000 ounces have been delivered, 55 ounces per million pounds for the next 225,000 ounces, and 45 ounces per million pounds thereafter.

First Quantum will receive 20 percent of the spot gold price per ounce delivered, rising to 35 percent if it secures a BB credit rating or maintains a net leverage ratio of 2.25x or lower for three straight quarters starting Q1 2026.

The deal also includes two optional acceleration provisions, allowing First Quantum to reduce future delivery commitments. The company can cut delivery thresholds by up to 20 percent at a value of up to US$200 million once it reaches the BB rating or leverage target.

A further 10 percent reduction, worth US$100 million, is possible upon achieving a leverage ratio of 1.25 times over four consecutive quarters, subject to meeting certain operational conditions.

The gold streaming deal is part of First Quantum’s continued efforts to strengthen its finances after recent setbacks at the Cobre Panamá mine.

In May, the company announced it had received government approval in Panama for its Preservation and Safe Management program at the Cobre Panamá mine. The approval enables the company to carry out environmental and safety measures funded through the export of 121,000 dry metric tons of copper concentrate currently stored on site.

The program does not represent a restart of full operations, but allows First Quantum to maintain the site and manage its obligations in line with Panamanian government requirements.

On the other hand, the deal also deepens Royal Gold’s exposure to a major African copper-gold asset at a time when the streaming and royalty company is making moves to expand its portfolio.

Just last month, Royal Gold announced a pair of major acquisitions: a US$3.5 billion all-share deal to acquire Sandstorm Gold (TSX:SSL)and a separate US$196 million cash deal for Horizon Copper (TSXV:HCU).

The transactions, announced in July, would create a streaming and royalty giant with 393 assets across six continents—including 80 that are currently cash-flowing.

Shares of First Quantum were up slightly in Tuesday trading following the announcement.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

In Investing

Crypto Market Update: Bitcoin ETFs Shed US$1.46B Amid Stagflation Jitters

August 6, 2025 No Comments

Here’s a quick recap of the crypto landscape for Wednesday (August 6) as of 9:00 a.m. UTC.

Get the latest insights on Bitcoin, Ethereum and altcoins, along with a round-up of key cryptocurrency market news.

Bitcoin and Ethereum price update

Bitcoin (BTC) was priced at US$114,217, down by 0.8 percent over the last 24 hours. Its highest valuation on Wednesday was US$112,770, while its lowest valuation was US$114,830.

Bitcoin price performance, August 6, 2025.

Chart via TradingView

Bitcoin is showing signs of support between US$117,000 and US$118,000, with technical analysts suggesting a possible rebound toward resistance levels at US$120,250 and beyond, if bullish momentum builds.

However, sentiment remains cautious amid ongoing interest rate uncertainty, macroeconomic pressures and ETF outflows, all of which are weighing on near-term price action.

Ethereum (ETH) was priced at US$3,619.63, down by 1.4 percent over the past 24 hours. Its lowest valuation on Wednesday was US$3,557.78, and its highest was US$3,673.

Altcoin price update

Solana (SOL) was priced at US$164.44, down by 3.9 percent over 24 hours. Its lowest valuation on Wednesday was US$161.45, and its highest was US$170.84.

XRP was trading for US$2.95, down by 3.8 percent in the past 24 hours. Its lowest valuation of the day was US$2.91, and its highest valuation was US$3.06.

Sui (SUI) is trading at US$3.41, down 4.2 percent over the past 24 hours. Its lowest valuation of the day was US$3.34, and its highest was US$3.55.

Cardano (ADA) was trading at US$0.7274, down by 3.2 percent over 24 hours. Its lowest valuation on Wednesday was US$0.7117, and its highest was US$0.751.

Today’s crypto news to know

Bitcoin ETFs see four days of outflows as stagflation fears ramp up

Spot bitcoin ETFs in the US recorded net outflows for the fourth day in a row, shedding nearly US$200 million on Tuesday alone.

Fidelity’s FBTC and BlackRock’s IBIT were the biggest sources of withdrawals, contributing to a total outflow of US$1.46 billion since last Thursday.

The trigger appears to be rising concerns around stagflation, following weaker-than-expected US service sector data.

The ISM Non-Manufacturing PMI pointed to slowing growth, declining employment, and rising prices, which represents a toxic mix for risk assets like crypto and tech stocks.

Bitcoin slipped below US$113,000 before recovering slightly, while the Nasdaq also dropped 0.7 percent on the day.

Meanwhile, bets on Federal Reserve rate cuts are growing, but uncertainty remains high.

SBI Files Japan’s first Bitcoin–XRP ETF application

Japanese financial giant SBI Holdings has filed for an ETF that includes both Bitcoin and XRP, aiming to offer regulated dual-crypto exposure in Japan.

The proposed product, revealed in SBI’s Q2 earnings report, would allow investors to track the performance of both assets in a single fund, a rare pairing in the global ETF space.

A second ETF proposal, the Digital Gold Crypto ETF, blends over 50% exposure to traditional gold ETFs with crypto assets backed by gold. This hybrid structure targets more conservative investors looking for crypto upside with commodity stability.

If approved, this would mark the first time XRP is included in a regulated ETF product in Japan, as it continues to face institutional barriers in the US due to its regulatory history.

Liquid staking is not a securities offering — SEC clarifies

In a major development for the crypto industry, the SEC’s Division of Corporation Finance stated that certain types of liquid staking do not constitute the sale of securities, according to a statement.

Specifically, tokenized staking receipt products, such as staked ETH derivatives, are not considered investment contracts unless they’re bundled into schemes that meet the legal definition.

This clarification provides a green light for platforms offering protocol-level staking services without requiring registration. Liquid staking allows users to earn rewards while still being able to trade or use a representative token, maintaining asset flexibility.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

In Investing

Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

August 6, 2025 No Comments

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (‘Cardiol‘ or the ‘Company‘), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced topline results from ARCHER, the Company’s Phase II clinical trial in patients with acute myocarditis. In the two primary endpoints—extracellular volume (‘ECV’) and global longitudinal strain (‘GLS’)—CardiolRx showed a notable improvement in ECV (p = 0.0538) compared to placebo following 12 weeks of double-blind therapy, with no significant difference observed in GLS in a population that had preserved left ventricular (‘LV’) function at baseline. The reduction in ECV was associated with improvements over placebo in multiple pre-specified cardiac magnetic resonance imaging (‘CMR’) endpoints, including a significant reduction in LV mass. The ARCHER trial results provide compelling clinical proof of concept for CardiolRx and strongly support advancing the clinical development of CardiolRx and CRD-38 in cardiomyopathies, heart failure, and myocarditis. Consistent with findings from Cardiol’s Phase II MAvERIC trial in recurrent pericarditis, CardiolRx was shown to be safe and well tolerated. The ARCHER results have been submitted for presentation at an upcoming scientific meeting and will be submitted for publication.

Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRx over placebo.
Reduction in ECV was associated with improvements across multiple pre-specified cardiac magnetic resonance imaging (CMR) endpoints, including a significant reduction in LV mass.
The ARCHER trial results provide compelling clinical proof of concept for CardiolRx and strongly support advancing the clinical development of CardiolRx and CRD-38 in cardiomyopathies, heart failure, and myocarditis.
The ARCHER results have been submitted for presentation at an upcoming scientific meeting and will be submitted for publication.

‘On behalf of the ARCHER Steering Committee, I would like to extend our sincere gratitude to the patients who participated in the study; to their families and caregivers for their invaluable support; and to the clinical trial site investigators and staff, members of the international Steering Committee, and the Data and Safety Monitoring Committee, whose exemplary efforts in patient recruitment, clinical care, trial execution, monitoring, and oversight were instrumental in achieving the compelling findings of the ARCHER trial,’ said Dr. Dennis M. McNamara, Professor of Medicine at the University of Pittsburgh, Director of the Center for Heart Failure Research at the University of Pittsburgh Medical Center, and Chair of the ARCHER Steering Committee. ‘I commend Cardiol for undertaking this important trial that investigated the biological effects of pharmaceutically manufactured cannabidiol in acute myocarditis. The results offer exciting new insights into the treatment of acute myocarditis and strongly support advancing the clinical development of this novel therapeutic approach for inflammatory cardiac conditions, including myocarditis and heart failure. I look forward to collaborating with my colleagues on the Steering Committee as we prepare for the presentation and publication of the comprehensive ARCHER trial data.’

Dr. Leslie T. Cooper, Jr., the Elizabeth C. Lane, Ph.D. and M. Nadine Zimmerman, Ph.D. Professor of Internal Medicine at the Mayo Clinic in Jacksonville, Florida, and Co-Chair of the Steering Committee for the ARCHER trial, added, ‘ARCHER was an important, well-designed, and well-executed clinical trial. The intriguing findings reinforce our original hypothesis that pharmaceutically manufactured cannabidiol can attenuate myocardial inflammation and edema. ARCHER’s results provide sound rationale for advancing the clinical development of this novel therapy in conditions of the myocardium characterized by edema, fibrosis, and remodeling, including the growing challenge of immune checkpoint inhibitor-induced myocarditis which can be fatal.’

‘We are delighted with the ARCHER trial results,’ said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics. ‘We initiated this ambitious study—focused on a potentially life-threatening cardiac disorder for which there is no established standard of care—to further investigate the therapeutic potential of CardiolRx in inflammatory heart disease. We are thrilled to observe improvements in multiple CMR measures associated with diagnosis, prognosis, and clinical outcomes. As we continue to advance our lead clinical program, the pivotal Phase III MAVERIC trial in recurrent pericarditis, we now look forward to integrating the ARCHER findings into our broader clinical development strategy and business development initiatives—supporting the continued advancement of CardiolRx and CRD-38 as potential treatments for inflammatory cardiac disorders.’

ARCHER is a Phase II multi-national, randomized, double-blind, placebo-controlled trial investigating the safety, tolerability, and impact of CardiolRx on myocardial recovery in patients presenting with acute myocarditis. The design and rationale for ARCHER were published on June 27, 2024, in the journal ESC Heart Failure. The study enrolled 109 patients from leading cardiovascular research centers in the United States, France, Brazil, and Israel. The two primary outcome measures of the trial, which were evaluated following 12 weeks of double-blind therapy, consist of cardiac magnetic resonance imaging parameters: extra-cellular volume and global longitudinal strain, which assess myocardial function and tissue characteristics associated with fibrosis and inflammation.

Acute Myocarditis

Acute myocarditis is an inflammatory condition of the heart muscle (myocardium) characterized by chest pain, shortness of breath at rest or during activity, fatigue, rapid or irregular heartbeat (arrhythmias), and light-headedness or the feeling one might faint. The disease is an important cause of acute and fulminant heart failure and is a leading cause of sudden cardiac death in people under 35 years of age. Viral infection is the most common cause of myocarditis; however, it can also result from bacterial infection, commonly used drugs, and mRNA vaccines, as well as therapies used to treat several common cancers, including chemo-therapeutic agents and immune checkpoint inhibitors. There are no FDA-approved drug therapies for acute myocarditis. Patients hospitalized with the condition experience an average seven-day length of stay and a 4 – 6% risk of in-hospital mortality, with average hospital charge per stay estimated at $110,000 in the United States.

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead small molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.

Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration (‘US FDA’) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The completed ARCHER trial (NCT05180240) is a Phase II study in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age. The US FDA has granted Orphan Drug Designation to CardiolRx for the treatment of pericarditis, which includes recurrent pericarditis.

Cardiol is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure—a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding $30 billion annually.

For more information about Cardiol Therapeutics, please visit cardiolrx.com.

Cautionary statement regarding forward-looking information:

This news release contains ‘forward-looking information’ within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are ‘forward-looking information’. Forward-looking information contained herein may include, but is not limited to statements regarding the Company’s focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, the Company’s intended clinical studies and trial activities and timelines associated with such activities, including the Company’s plan to complete the Phase III study in recurrent pericarditis with CardiolRx, the Company’s plan to advance the development of CRD-38, a novel subcutaneous formulation of cannabidiol intended for use in heart failure, the Company’s presentation and publication of the comprehensive ARCHER trial data, and the Company’s belief that results from the ARCHER trial provide compelling clinical proof of concept for CardiolRx and strongly support advancing the clinical development of CardiolRx and CRD-38 for the treatment of inflammatory cardiac disorders including cardiomyopathies, heart failure, and myocarditis. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company’s Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2025, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.

For further information, please contact:
Trevor Burns, Investor Relations +1-289-910-0855
trevor.burns@cardiolrx.com

Click here to connect with Cardiol Therapeutics Inc. to receive an Investor Presentation

Source

This post appeared first on investingnews.com

In Investing

Seismic Equipment Arrives For Enercam Resources’ Oil & Gas Block VIII, Cambodia

August 6, 2025 No Comments

(TheNewswire)

GRANDE PRAIRIE, ALBERTA – August 6, 2025 TheNewswire – Angkor Resources Corp. (TSXV: ANK,OTC:ANKOF) (‘ANGKOR’ OR ‘THE COMPANY’) announces its subsidiary, EnerCam Resources Co. Ltd. (Cambodia) (‘EnerCam’) has landed seismic equipment from seismic contractor GeneSeis Company Limited Thailand (‘GeneSeis’) to commence Cambodia’s first onshore EnviroVibe oil and gas seismic for Block VIII (‘Project’).

Keith Edwards, Technical Manager of EnerCam, comments on the start of this type of seismic, ‘This program will provide comprehensive coverage over Block VIII and will guide our efforts going forward. We are excited about this search for Cambodia’s first site for onshore oil and gas production and hopefully this seismic will lead to the first onshore well being drilled in Cambodia.’

Due to border conflict issues which started in May and ceasefire agreements in late July, the equipment could not pass through land borders and therefore, five containers came into Sihanoukville port by ship and then were transported to the base camp of the seismic program.

Seismic teams are executing 350-line kilometers of two dimensional seismic over four identified sub basins on the west side of the license area plus a newly described ‘mussel basin’ on the northeast side of the license.

Mike Weeks, President of EnerCam, states, ‘We are very pleased to be starting this seismic program on Block VIII; it is a huge milestone for both the company and the country. Overcoming the hurdles is a tribute to the team and we are expecting to see this program provide significant data towards drill targets for Cambodia’s onshore oil and gas industry.’

Following a multitude of scoping missions by the lead geoscientists of EnerCam, accompanied by graduate students from Institute of Technology of Cambodia (ITC) and logistics manager Bunchhay Yun, the team now prepares to start an environmentally friendly seismic program in the Kingdom of Cambodia. Keith Edwards, Technical Manager for EnerCam explains, ‘The EnviroVibe units use no dynamite but instead use the weight of the vehicle and a hydraulicly controlled vibrating pad to send acoustic (sound) waves into the sub-surface. This vibration is done with frequencies of 3-80Hz, 3 times for 12 seconds each time using two EnviroVibe vehicles that are synchronized. By spreading the energy over 36 seconds, we can operate in many environments with no negative impacts.’

Management is expecting noise from rainfall or traffic to have less impact on the VibroSeis data than traditional impulsive sources such as dynamite or weight drop. Specific plans were made on access points to mitigate this and recent adjustments incorporated that into the planned program.

The teams have driven over 3720 kilometers, spent several weeks between May and July confirming the best routes to take for quality data, and have taken over 2900 photos of terrain as part of the data collection prior to seismic lines.

Between 35-40 personnel are now deployed to execute the 2-D seismic over the verified roads and access points. All affected landowners, community and commune authorities have been contacted and have given permission for EnerCam to proceed. The program started yesterday and is expected to take a minimum of four weeks to cover the destination routes to acquire the necessary data.

Click Image To View Full Size

Figure 1 Mike Weeks in foreground of Envirovibe machine and several staff sorting

through some of the 2000+ geophones.

Figure 2: Over 2000 geophones, which convert ground movement into voltage, form part of the equipment for the 350 line kilometers from which vibrations will be measured.

Click Image To View Full Size

Figure 3 New Oil Seeps identified on most the recent Scouting Mission on July 29 2025.

ABOUT Angkor Resources CORPORATION:

Angkor Resources Corp. is a public company, listed on the TSX-Venture Exchange, and is a leading resource optimizer in Cambodia working towards mineral and energy solutions across Canada and Cambodia. ANGKOR’s carbon capture and gas conservation project in Saskatchewan, Canada is part of its long-term commitment to Environmental and Social projects and cleaner energy solutions across jurisdictions. The company’s mineral subsidiary, Angkor Gold Corp. in Cambodia holds three mineral exploration licenses in Cambodia and its Cambodian energy subsidiary, EnerCam Resources, was granted an onshore oil and gas license of 7300 square kilometers in the southwest quadrant of Cambodia called Block VIII. The company then removed all parks and protected areas to reduce the size to just over 3700 square kilometers. Since 2022, Angkor’s Canadian subsidiary, EnerCam Exploration Ltd., has been involved in gas/carbon capture and oil and gas production in Saskatchewan, Canada.

CONTACT: Delayne Weeks – CEO

Email: info@angkorresources.com Website: angkor resources.com Telephone: +1 (780) 831-8722

Please follow @AngkorResources on , , , Instagram and .

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including, but not limited to the potential for gold and/or other minerals at any of the Company’s properties, the prospective nature of any claims comprising the Company’s property interests, the impact of general economic conditions, industry conditions, dependence upon regulatory approvals, uncertainty of sample results, timing and results o f future exploration, and the availability of financing. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.

News Provided by TheNewsWire via QuoteMedia

This post appeared first on investingnews.com

In Latest News

SCOOP: Trump admin, OpenAI partner to unleash artificial intelligence on federal government

August 6, 2025 No Comments

The federal government is stepping into the future and embracing artificial intelligence, specifically ChatGPT, across its agencies, which proponents say will streamline productivity while solidifying President Donald Trump’s pledge to keep the U.S. in the driver’s seat of the cutting-edge technology, Fox News Digital exclusively learned.

The U.S. General Services Administration announced Wednesday that OpenAI’s ChatGPT Enterprise is now available to all federal agencies to incorporate into their workflow at a $1 per agency cost, the GSA told Fox Digital. The deal with OpenAI, the tech company behind ChatGPT, is part of GSA’s OneGov Strategy that aims to modernize ‘how the federal government purchases goods and services’ under the Trump administration.

‘The use of this tool has been deployed and tested with responsible policy makers, with responsible legal folks,’ GSA Federal Acquisition Service Commissioner Josh Gruenbaum told Fox News Digital of integrating AI into the federal government. ‘It’s not just auto-piloting and saying, ‘go machine’ and we just respond. … It’s automation, it’s ease of processes, but it’s also thinking about … the typical waste, fraud and abuse that we’re also focused on with this administration.’

ChatGPT is a wildly popular AI chatbot that can hold conversational discussions, provide research accompanied by citations, automate routine tasks such as data entry or file processing, summarize books or lengthy files, and even assist with brainstorming project ideas or problem-solving tasks.

‘Open AI just announced the ChatGPT has over 700 million weekly users, so the amount of commercial adoption is quite astounding,’ OpenAI’s Joseph Larson told Fox Digital Tuesday of the partnership. ‘What we didn’t want to see was a gap between the tools available for artificial intelligence to the federal workforce, a gap between what is available in … the private sector or available to the public. So with this GSA partnership, what the administration is doing, which we believe to be in line with the AI action plan, is to make ChatGPT Enterprise, which is … the most advanced AI tools available to the entire federal government will now be available to all agencies of the federal government at the nominal cost of $1 per agency.’

How federal agencies employ the technology will likely range from department to department, with employees offered access ‘to a new government user community and tailored introductory training resources’ as well as ‘custom training platforms and guided learning, either directly or through partner-led sessions’ to best fit their needs.

‘One of the best ways to make sure AI works for everyone is to put it in the hands of the people serving our country,’ OpenAI CEO Sam Altman said of the partnership in a Wednesday press release. ‘We’re proud to partner with the General Services Administration, delivering on President Trump’s AI Action Plan, to make ChatGPT available across the federal government, helping public servants deliver for the American people.’

The Trump administration rolled ut its AI Action Plan in July after Trump ordered the federal government in January to develop a plan of action for artificial intelligence in order to ‘solidify our position as the global leader in AI and secure a brighter future for all Americans.’

The AI Action Plan includes a three-pillar approach focused on American workers, free speech and protecting U.S.-built technologies.

‘We want to center America’s workers, and make sure they benefit from AI,’ AI and crypto czar David Sacks told the media in July of the AI plan.

‘The second is that we believe that AI systems should be free of ideological bias and not be designed to pursue socially engineered agendas,’ Sacks said. ‘And so we have a number of proposals there on how to make sure that AI remains truth-seeking and trustworthy. And then the third principle that cuts across the pillars is that we believe we have to prevent our advanced technologies from being misused or stolen by malicious actors. And we also have to monitor for emerging and unforeseen risks from AI.’

Gruenbaum told Fox Digital that when the GSA reviewed the administration’s AI action plan, it jumped at rolling out ‘widespread adoption’ for the government to help answer Trump’s call for the U.S. to stay on top of the artificial intelligence race on the global stage.

‘Where we see ourselves playing, obviously, is through a lot of the Federal Acquisition Service, which is the largest procurement arm in the federal government,’ he said. ‘And as we kind of examined the President’s AI action plan, heard the call to action of, ‘Hey, this is a race, and we are going to win this race.’ From our perspective, all that meant, synonymously, was widespread adoption. Those were the words, quite frankly, that the OpenAI team used to us in our very first call. And their call to action was, ‘we need to get this into the hands of as many federal workers as possible.’ We at the GSA took that extremely seriously.’

‘Everything’s kind of leading to the place of having us poised for this AI revolution,’ he added.

The Trump administration has notched massive wins in the artificial intelligence race, which has pitted the U.S. against China to develop the most high-tech artificial intelligence systems, including Oracle and OpenAI announcing in July that the companies will further develop the Stargate project, which is an effort to launch large data centers in the U.S. The two companies’ most recent announcement promises an additional 4.5 gigawatts of Stargate data center capacity, a move expected to create more than 100,000 jobs across operations, construction, and indirect roles such as manufacturing and local services.

The Stargate project includes a commitment from OpenAI, Oracle, SoftBank and MGX to invest $500 billion in U.S.-based artificial intelligence infrastructure throughout the next four years.

This post appeared first on FOX NEWS

In Investing